One of the most difficult aspects of patenting antibodies and other biologics is obtaining sufficiently broad patent protection. In order to claim a genus of antibodies, rather than specific sequences, the applicant must...more
Since 1999, the United States Patent and Trademark Office (“Patent Office”) has permitted the claiming of antibodies by disclosing the targeted antigen. In 2002, the Federal Circuit adopted Patent Office guidelines and...more
3/26/2018
/ Amgen ,
Life Sciences ,
MPEP ,
New Guidance ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sanofi ,
USPTO ,
Written Descriptions
The United States Court of Appeals for the Federal Circuit (“Federal Circuit”) addressed the pleading standards for direct infringement, doctrine of equivalents infringement, indirect infringement and willful infringement in...more
3/8/2018
/ Amended Complaints ,
Appeals ,
Claim Construction ,
Direct Infringement ,
Dismissals ,
Doctrine of Equivalents ,
Failure To State A Claim ,
FRCP 8 ,
Indirect Infringement ,
Patent Infringement ,
Patents ,
Pleading Standards ,
Reversal ,
Twombly/Iqbal Pleading Standard ,
Willful Infringement